Harvard Bioscience logo

Harvard BioscienceNASDAQ: HBIO

Profile

Sector:

Healthcare

Country:

United States

IPO:

19 March 2001

Next earnings report:

07 March 2025

Last dividends:

N/A

Next dividends:

N/A
$94.21 M
-68%vs. 3y high
44%vs. sector
-vs. 3y high
-vs. sector
-63%vs. 3y high
48%vs. sector
-63%vs. 3y high
24%vs. sector

Price

after hours | Wed, 20 Nov 2024 21:25:55 GMT
$2.16+$0.01(+0.47%)

Dividend

No data over the past 3 years
$21.97 M$24.15 M
$21.97 M-$4.80 M

Analysts recommendations

Institutional Ownership

HBIO Latest News

Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: NEUTRAL

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Third Quarter 2024 Harvard Biosciences Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded.

Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
globenewswire.com29 October 2024 Sentiment: NEUTRAL

HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
globenewswire.com18 September 2024 Sentiment: POSITIVE

Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development

Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
globenewswire.com05 September 2024 Sentiment: POSITIVE

HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Small Cap Virtual Conference on September 18th, 2024, with a presentation time of 9:15 am ET.

Harvard Bioscience, Inc. (HBIO) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: POSITIVE

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2024 Earnings Conference Call August 8, 2024 10:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Bruce Jackson - The Benchmark Company Christopher Sakai - Singular Research Operator Good day, and thank you for standing by. Welcome to the Q2 2024 Harvard Bioscience, Inc. Earnings Conference Call.

Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
globenewswire.com02 August 2024 Sentiment: POSITIVE

HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m. Eastern Time.

Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
globenewswire.com06 June 2024 Sentiment: POSITIVE

HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024.

Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
globenewswire.com16 May 2024 Sentiment: POSITIVE

Harvard Bioscience, Inc. (Nasdaq: HBIO) disclosed that Jim Green, Chairman and CEO, and Jennifer Cote, CFO, will take part in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, including a live fireside chat at 9:00-9:40 am ET. The Company will also hold individual meetings with investors during the Conference.

Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
GlobeNewsWire29 April 2024 Sentiment: POSITIVE

Harvard Bioscience, Inc. (Nasdaq: HBIO) is scheduled to release its financial results for the quarter ending on March 31, 2024 before the market opens on May 7, 2024. A conference call to discuss the results will take place at 8:00 a.m. Eastern Time.

Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti's Small Cap Conference and KeyBanc's Life Sciences & MedTech Conference
GlobeNewsWire11 March 2024 Sentiment: POSITIVE

HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be held virtually in March 2024. Joining him will be Jennifer Cote, the Company's Chief Financial Officer.

  • 1(current)

What type of business is Harvard Bioscience?

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

What sector is Harvard Bioscience in?

Harvard Bioscience is in the Healthcare sector

What industry is Harvard Bioscience in?

Harvard Bioscience is in the Medical Instruments & Supplies industry

What country is Harvard Bioscience from?

Harvard Bioscience is headquartered in United States

When did Harvard Bioscience go public?

Harvard Bioscience initial public offering (IPO) was on 19 March 2001

What is Harvard Bioscience website?

https://www.harvardbioscience.com

Is Harvard Bioscience in the S&P 500?

No, Harvard Bioscience is not included in the S&P 500 index

Is Harvard Bioscience in the NASDAQ 100?

No, Harvard Bioscience is not included in the NASDAQ 100 index

Is Harvard Bioscience in the Dow Jones?

No, Harvard Bioscience is not included in the Dow Jones index

When was Harvard Bioscience the previous earnings report?

No data

When does Harvard Bioscience earnings report?

The next expected earnings date for Harvard Bioscience is 07 March 2025